DocMorris, the online pharmacy, has had its price target downgraded by UBS from 27 to 25 Swiss francs. UBS maintains a "Sell" rating and expresses concerns about the company's growth prospects in the German prescription drug market, suggesting a potential slowdown in business performance in the near future.
UBS's revised target reflects their cautious outlook on DocMorris as they analyze the competitive landscape and market dynamics of the online pharmacy sector.
The analysis was published on October 16, 2024, and disseminated shortly after.